As the pharmaceutical industry continues to advance, there is an increasing number of identified drug targets and new modalities that require novel small molecule space.

MyxoTech offers a library of novel chemistry produced by a group of bacteria that exist on the fringe of microbial dark matter. This pool of small molecules contains proven bioactives that act on diverse targets. Corallopyronin A, projected for phase I clinical trials in 2026 for treatment of filarial infection, and breast cancer drug Ixabepilone's precursor epothilone B exemplify the value of the library.

We additionally provide a menu of downstream services, including drug lead and production titer optimization.

MyxoTech is an outsourced preclinical natural product pipeline adaptable for you drug development needs.

MyxoTech

Org chart

Teams

Offices